Clinical Trial Update: Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating whether ocrelizumab reduces neuroinflammation in multiple sclerosis as measured by 11C-PBR28 MR-PET imaging of microglia activation; re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Ocrelizumab (ocrelizumab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Multiple Sclerosis | Phase 4 | Status: COMPLETED | Results posted: 2025-12-30